Skip to main content

Advertisement

SpringerLink
Log in

Management of hereditary medullary thyroid carcinoma

  • Review
  • Published:
Endocrine Aims and scope Submit manuscript

Abstract

Hereditary medullary thyroid carcinoma (MTC) represents up to one-third of MTC cases and includes multiple endocrine neoplasia syndrome type 2A (and its variant familial MTC) and 2B. The aim of this paper is to provide an overview of the disease focusing on the management of hereditary MTC patients, who have already developed tumor, as well as discuss the recommended approach for asymptomatic family members carrying the same mutation. A PubMed search was performed to review recent literature on diagnosis, genetic testing, and surgical and medical management of hereditary MTC. The wide use of genetic testing for RET mutations has markedly influenced the course of hereditary MTC. Prophylactic thyroidectomy of RET carriers at an early age eliminates the risk of developing MTC later in life. Pre-operative staging is a strong prognostic factor in patients, who have developed MTC. The use of recently approved tyrosine kinase inhibitors (vandetanib, cabozantinib) holds promising results for the treatment of unresectable, locally advanced, and progressive metastatic MTC. Genetic testing of the RET gene is a powerful tool in the diagnosis and prognosis of MTC. Ongoing research is expected to add novel treatment options for patients with advanced, progressive disease.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. J.B. Hazard, W.A. Hawk, G. Crile Jr, Medullary (solid) carcinoma of the thyroid; a clinicopathologic entity. J. Clin. Endocrinol. Metab. 19(1), 152–161 (1959). doi:10.1210/jcem-19-1-152

    Article  CAS  PubMed  Google Scholar 

  2. S.A. Wells Jr, S.L. Asa, H. Dralle, R. Elisei, D.B. Evans, R.F. Gagel, N. Lee, A. Machens, J.F. Moley, F. Pacini, F. Raue, K. Frank-Raue, B. Robinson, M.S. Rosenthal, M. Santoro, M. Schlumberger, M. Shah, S.G. Waguespack, American Thyroid Association Guidelines Task Force on Medullary Thyroid, C.: revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma. Thyroid 25(6), 567–610 (2015). doi:10.1089/thy.2014.0335

    Article  PubMed  PubMed Central  Google Scholar 

  3. Y. Ishizaka, F. Itoh, T. Tahira, I. Ikeda, T. Sugimura, J. Tucker, A. Fertitta, A.V. Carrano, M. Nagao, Human ret proto-oncogene mapped to chromosome 10q11.2. Oncogene 4(12), 1519–1521 (1989)

    CAS  PubMed  Google Scholar 

  4. C.J. Lips, R.M. Landsvater, J.W. Hoppener, R.A. Geerdink, G. Blijham, J.M. van Veen, A.P. van Gils, M.J. de Wit, R.A. Zewald, M.J. Berends et al., Clinical screening as compared with DNA analysis in families with multiple endocrine neoplasia type 2A. N. Engl. J. Med. 331(13), 828–835 (1994). doi:10.1056/NEJM199409293311302

    Article  CAS  PubMed  Google Scholar 

  5. C. Romei, A. Tacito, E. Molinaro, L. Agate, V. Bottici, D. Viola, A. Matrone, A. Biagini, F. Casella, R. Ciampi, G. Materazzi, P. Miccoli, L. Torregrossa, C. Ugolini, F. Basolo, P. Vitti, R. Elisei, Twenty years of lesson learning: how does the RET genetic screening test impact the clinical management of medullary thyroid cancer? Clin Endocrinol (Oxf) 82(6), 892–899 (2015). doi:10.1111/cen.12686

    Article  CAS  Google Scholar 

  6. H.L. Sarika, A. Papathoma, M. Garofalaki, V. Vasileiou, B. Vlassopoulou, E. Anastasiou, M. Alevizaki, High prevalence of exon 8 G533C mutation in apparently sporadic medullary thyroid carcinoma in Greece. Clin Endocrinol (Oxf) 77(6), 857–862 (2012). doi:10.1111/j.1365-2265.2012.04462.x

    Article  CAS  Google Scholar 

  7. http://www.arup.utah.edu/database/MEN2/MEN2_welcome.php

  8. T. Pappa, M. Alevizaki, The value of genetic screening in medullary thyroid cancer. Expert Rev Endocrinol Metab 9(1), 19–29 (2014). doi:10.1586/17446651.2014.868772

    Article  CAS  Google Scholar 

  9. M. Alevizaki, K. Saltiki, T. Pappa, Medullary Thyroid Carcinoma, Reference Module in Biomedical Sciences (Elsevier, Amsterdam, 2015)

    Google Scholar 

  10. M. Alevizaki, K. Saltiki, Primary hyperparathyroidism in MEN2 syndromes. Recent Results Cancer Res. 204, 179–186 (2015). doi:10.1007/978-3-319-22542-5_8

    Article  PubMed  Google Scholar 

  11. I. Ceccherini, C. Romei, V. Barone, F. Pacini, E. Martino, A. Loviselli, A. Pinchera, G. Romeo, Identification of the Cys634– > Tyr mutation of the RET proto-oncogene in a pedigree with multiple endocrine neoplasia type 2A and localized cutaneous lichen amyloidosis. J. Endocrinol. Invest. 17(3), 201–204 (1994)

    Article  CAS  PubMed  Google Scholar 

  12. K. Frank-Raue, L.A. Rybicki, Z. Erlic, H. Schweizer, A. Winter, I. Milos, S.P. Toledo, R.A. Toledo, M.R. Tavares, M. Alevizaki, C. Mian, H. Siggelkow, M. Hufner, N. Wohllk, G. Opocher, S. Dvorakova, B. Bendlova, M. Czetwertynska, E. Skasko, M. Barontini, G. Sanso, C. Vorlander, A.L. Maia, A. Patocs, T.P. Links, J.W. de Groot, M.N. Kerstens, G.D. Valk, K. Miehle, T.J. Musholt, J. Biarnes, S. Damjanovic, M. Muresan, C. Wuster, M. Fassnacht, M. Peczkowska, C. Fauth, H. Golcher, M.A. Walter, J. Pichl, F. Raue, C. Eng, H.P. Neumann, R.E.T.E.C. International, Risk profiles and penetrance estimations in multiple endocrine neoplasia type 2A caused by germline RET mutations located in exon 10. Hum. Mutat. 32(1), 51–58 (2011). doi:10.1002/humu.21385

    Article  CAS  PubMed  Google Scholar 

  13. E. Arighi, A. Popsueva, D. Degl’Innocenti, M.G. Borrello, C. Carniti, N.M. Perala, M.A. Pierotti, H. Sariola, Biological effects of the dual phenotypic Janus mutation of ret cosegregating with both multiple endocrine neoplasia type 2 and Hirschsprung’s disease. Mol. Endocrinol. 18(4), 1004–1017 (2004). doi:10.1210/me.2003-0173

    Article  CAS  PubMed  Google Scholar 

  14. S.W. Moore, M. Zaahl, Familial associations in medullary thyroid carcinoma with Hirschsprung disease: the role of the RET-C620 “Janus” genetic variation. J. Pediatr. Surg. 45(2), 393–396 (2010). doi:10.1016/j.jpedsurg.2009.10.080

    Article  PubMed  Google Scholar 

  15. M.N. Oliveira, J.P. Hemerly, A.U. Bastos, R. Tamanaha, F.R. Latini, C.P. Camacho, A. Impellizzeri, R.M. Maciel, J.M. Cerutti, The RET p. G533C mutation confers predisposition to multiple endocrine neoplasia type 2A in a Brazilian kindred and is able to induce a malignant phenotype in vitro and in vivo. Thyroid 21(9), 975–985 (2011). doi:10.1089/thy.2010.0190

    Article  CAS  PubMed  Google Scholar 

  16. S. Bethanis, G. Koutsodontis, T. Palouka, C. Avgoustis, D. Yannoukakos, T. Bei, S. Papadopoulos, D. Linos, S. Tsagarakis, A newly detected mutation of the RET protooncogene in exon 8 as a cause of multiple endocrine neoplasia type 2A. Hormones (Athens) 6(2), 152–156 (2007)

    Article  Google Scholar 

  17. O. Gimm, D.J. Marsh, S.D. Andrew, A. Frilling, P.L. Dahia, L.M. Mulligan, J.D. Zajac, B.G. Robinson, C. Eng, Germline dinucleotide mutation in codon 883 of the RET proto-oncogene in multiple endocrine neoplasia type 2B without codon 918 mutation. J. Clin. Endocrinol. Metab. 82(11), 3902–3904 (1997). doi:10.1210/jcem.82.11.4508

    Article  CAS  PubMed  Google Scholar 

  18. S. Jasim, A.K. Ying, S.G. Waguespack, T.A. Rich, E.G. Grubbs, C. Jimenez, M.I. Hu, G. Cote, M.A. Habra, Multiple endocrine neoplasia type 2B with a RET proto-oncogene A883F mutation displays a more indolent form of medullary thyroid carcinoma compared with a RET M918T mutation. Thyroid 21(2), 189–192 (2011). doi:10.1089/thy.2010.0328

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. B. Cosci, A. Vivaldi, C. Romei, F. Gemignani, S. Landi, R. Ciampi, A. Tacito, E. Molinaro, L. Agate, V. Bottici, V. Cappagli, D. Viola, P. Piaggi, P. Vitti, A. Pinchera, R. Elisei, In silico and in vitro analysis of rare germline allelic variants of RET oncogene associated with medullary thyroid cancer. Endocr. Relat. Cancer 18(5), 603–612 (2011). doi:10.1530/ERC-11-0117

    Article  CAS  PubMed  Google Scholar 

  20. K.T. Nakao, T. Usui, M. Ikeda, Y. Mori, T. Yamamoto, S.T. Kawashima, K. Nanba, A. Yuno, T. Tamanaha, T. Tagami, M. Naruse, R. Asato, A. Shimatsu, Novel tandem germline RET proto-oncogene mutations in a patient with multiple endocrine neoplasia type 2B: report of a case and a literature review of tandem RET mutations with in silico analysis. Head Neck 35(12), E363–E368 (2013). doi:10.1002/hed.23241

    Article  PubMed  Google Scholar 

  21. D.K. Bartsch, C. Hasse, C. Schug, P. Barth, M. Rothmund, W. Hoppner, A RET double mutation in the germline of a kindred with FMTC. Exp. Clin. Endocrinol. Diabetes 108(2), 128–132 (2000). doi:10.1055/s-2000-5806

    Article  CAS  PubMed  Google Scholar 

  22. H.L. Sarika, A. Papathoma, M. Garofalaki, K. Saltiki, T. Pappa, K. Pazaitou-Panayiotou, E. Anastasiou, M. Alevizaki, Genetic screening of patients with medullary thyroid cancer in a referral center in Greece during the past two decades. Eur. J. Endocrinol. 172(4), 501–509 (2015). doi:10.1530/EJE-14-0817

    Article  CAS  PubMed  Google Scholar 

  23. A. Machens, K. Lorenz, C. Sekulla, W. Hoppner, K. Frank-Raue, F. Raue, H. Dralle, Molecular epidemiology of multiple endocrine neoplasia 2: implications for RET screening in the new millenium. Eur. J. Endocrinol. 168(3), 307–314 (2013). doi:10.1530/EJE-12-0919

    Article  CAS  PubMed  Google Scholar 

  24. Romei, C., Mariotti, S., Fugazzola, L., Taccaliti, A., Pacini, F., Opocher, G., Mian, C., Castellano, M., degli Uberti, E., Ceccherini, I., Cremonini, N., Seregni, E., Orlandi, F., Ferolla, P., Puxeddu, E., Giorgino, F., Colao, A., Loli, P., Bondi, F., Cosci, B., Bottici, V., Cappai, A., Pinna, G., Persani, L., Verga, U., Boscaro, M., Castagna, M.G., Cappelli, C., Zatelli, M.C., Faggiano, A., Francia, G., Brandi, M.L., Falchetti, A., Pinchera, A., Elisei, R., Ita, M.E.N.n.: Multiple endocrine neoplasia type 2 syndromes (MEN 2): results from the ItaMEN network analysis on the prevalence of different genotypes and phenotypes. Eur. J. Endocrinol. 163(2), 301–308 (2010). doi:10.1530/EJE-10-0333

  25. T. Pappa, The role of genetic screening in medullary thyroid cancer: a clinician’s view on the recent ATA guidelines. Expert Rev Endocrinol Metab 10(4), 345–347 (2015). doi:10.1586/17446651.2015.1057121

    Article  CAS  Google Scholar 

  26. V. Rohmer, G. Vidal-Trecan, A. Bourdelot, P. Niccoli, A. Murat, J.L. Wemeau, F. Borson-Chazot, C. Schvartz, A. Tabarin, O. Chabre, G. Chabrier, P. Caron, P. Rodien, M. Schlumberger, E. Baudin, E. Groupe Francais des Tumeurs, Prognostic factors of disease-free survival after thyroidectomy in 170 young patients with a RET germline mutation: a multicenter study of the Groupe Francais d’Etude des Tumeurs Endocrines. J. Clin. Endocrinol. Metab. 96(3), E509–E518 (2011). doi:10.1210/jc.2010-1234

    Article  CAS  PubMed  Google Scholar 

  27. R. Elisei, C. Romei, G. Renzini, V. Bottici, B. Cosci, E. Molinaro, L. Agate, V. Cappagli, P. Miccoli, P. Berti, P. Faviana, C. Ugolini, F. Basolo, P. Vitti, A. Pinchera, The timing of total thyroidectomy in RET gene mutation carriers could be personalized and safely planned on the basis of serum calcitonin: 18 years experience at one single center. J. Clin. Endocrinol. Metab. 97(2), 426–435 (2012). doi:10.1210/jc.2011-2046

    Article  CAS  PubMed  Google Scholar 

  28. A. Machens, K. Lorenz, H. Dralle, Individualization of lymph node dissection in RET (rearranged during transfection) carriers at risk for medullary thyroid cancer: value of pretherapeutic calcitonin levels. Ann. Surg. 250(2), 305–310 (2009). doi:10.1097/SLA.0b013e3181ae333f

    Article  PubMed  Google Scholar 

  29. K. Papaparaskeva, H. Nagel, M. Droese, Cytologic diagnosis of medullary carcinoma of the thyroid gland. Diagn. Cytopathol. 22(6), 351–358 (2000)

    Article  CAS  PubMed  Google Scholar 

  30. P. Trimboli, L. Guidobaldi, M. Bongiovanni, A. Crescenzi, M. Alevizaki, L. Giovanella, Use of fine-needle aspirate calcitonin to detect medullary thyroid carcinoma: a systematic review. Diagn. Cytopathol. (2015). doi:10.1002/dc.23375

    PubMed  Google Scholar 

  31. P. Trimboli, L. Guidobaldi, A. Crescenzi, M. Bongiovanni, L. Giovanella, The essential use of FNA-calcitonin for detecting medullary thyroid cancer. Endocrine 47(1), 342–344 (2014). doi:10.1007/s12020-014-0226-x

    Article  CAS  PubMed  Google Scholar 

  32. H.J. Wolfe, K.E. Melvin, S.J. Cervi-Skinner, A.A. Saadi, J.F. Juliar, C.E. Jackson, A.H. Tashjian Jr, C-cell hyperplasia preceding medullary thyroid carcinoma. N. Engl. J. Med. 289(9), 437–441 (1973). doi:10.1056/NEJM197308302890901

    Article  CAS  PubMed  Google Scholar 

  33. G.C. Pastolero, C.I. Coire, S.L. Asa, Concurrent medullary and papillary carcinomas of thyroid with lymph node metastases. A collision phenomenon. Am. J. Surg. Pathol. 20(2), 245–250 (1996)

    Article  CAS  PubMed  Google Scholar 

  34. K. Cheung, S.A. Roman, T.S. Wang, H.D. Walker, J.A. Sosa, Calcitonin measurement in the evaluation of thyroid nodules in the United States: a cost-effectiveness and decision analysis. J. Clin. Endocrinol. Metab. 93(6), 2173–2180 (2008). doi:10.1210/jc.2007-2496

    Article  CAS  PubMed  Google Scholar 

  35. M.G. Castagna, L. Fugazzola, F. Maino, D. Covelli, S. Memmo, F. Sestini, C. Fioravanti, C. Ferraris Fusarini, C. Scapellato, F. Macchini, G. Cevenini, F. Pacini, Reference range of serum calcitonin in pediatric population. J. Clin. Endocrinol. Metab. 100(5), 1780–1784 (2015). doi:10.1210/jc.2014-4508

    Article  CAS  PubMed  Google Scholar 

  36. L. Fugazzola, Stimulated calcitonin cut-offs by different tests. Eur. Thyroid. J. 2(1), 49–56 (2013). doi:10.1159/000346020

    CAS  PubMed  PubMed Central  Google Scholar 

  37. E.F. Brutsaert, A.J. Gersten, A.B. Tassler, M.I. Surks, Medullary thyroid cancer with undetectable serum calcitonin. J. Clin. Endocrinol. Metab. 100(2), 337–341 (2015). doi:10.1210/jc.2014-3095

    Article  CAS  PubMed  Google Scholar 

  38. P. Trimboli, E. Seregni, G. Treglia, M. Alevizaki, L. Giovanella, Procalcitonin for detecting medullary thyroid carcinoma: a systematic review. Endocr. Relat. Cancer 22(3), R157–R164 (2015). doi:10.1530/ERC-15-0156

    Article  PubMed  Google Scholar 

  39. T.D. Samulski, V.A. Livolsi, K. Montone, Z. Baloch, The variable pathologic presentations of medullary and micro-medullary thyroid carcinoma: an institutional experience. Pathol. Res. Pract. 210(3), 182–185 (2014). doi:10.1016/j.prp.2013.12.004

    Article  PubMed  Google Scholar 

  40. S. Guyetant, F. Dupre, J.C. Bigorgne, B. Franc, N. Dutrieux-Berger, M. Lecomte-Houcke, M. Patey, B. Caillou, G. Viennet, O. Guerin, J.P. Saint-Andre, Medullary thyroid microcarcinoma: a clinicopathologic retrospective study of 38 patients with no prior familial disease. Hum. Pathol. 30(8), 957–963 (1999)

    Article  CAS  PubMed  Google Scholar 

  41. V.G. Pillarisetty, S.C. Katz, R.A. Ghossein, R.M. Tuttle, A.R. Shaha, Micromedullary thyroid cancer: how micro is truly micro? Ann. Surg. Oncol. 16(10), 2875–2881 (2009). doi:10.1245/s10434-009-0595-1

    Article  PubMed  Google Scholar 

  42. K. Saltiki, G. Rentziou, K. Stamatelopoulos, G. Georgiopoulos, C. Stavrianos, E. Lambrinoudaki, M. Alevizaki, Small medullary thyroid carcinoma: post-operative calcitonin rather than tumour size predicts disease persistence and progression. Eur. J. Endocrinol. 171(1), 117–126 (2014). doi:10.1530/EJE-14-0076

    Article  CAS  PubMed  Google Scholar 

  43. C. Scollo, E. Baudin, J.P. Travagli, B. Caillou, N. Bellon, S. Leboulleux, M. Schlumberger, Rationale for central and bilateral lymph node dissection in sporadic and hereditary medullary thyroid cancer. J. Clin. Endocrinol. Metab. 88(5), 2070–2075 (2003). doi:10.1210/jc.2002-021713

    Article  CAS  PubMed  Google Scholar 

  44. A. Machens, H. Dralle, Prognostic impact of N staging in 715 medullary thyroid cancer patients: proposal for a revised staging system. Ann. Surg. 257(2), 323–329 (2013). doi:10.1097/SLA.0b013e318268301d

    Article  PubMed  Google Scholar 

  45. A. Machens, U. Schneyer, H.J. Holzhausen, H. Dralle, Prospects of remission in medullary thyroid carcinoma according to basal calcitonin level. J. Clin. Endocrinol. Metab. 90(4), 2029–2034 (2005). doi:10.1210/jc.2004-1836

    Article  CAS  PubMed  Google Scholar 

  46. A. Machens, S. Hauptmann, H. Dralle, Prediction of lateral lymph node metastases in medullary thyroid cancer. Br. J. Surg. 95(5), 586–591 (2008). doi:10.1002/bjs.6075

    Article  CAS  PubMed  Google Scholar 

  47. S. Roman, R. Lin, J.A. Sosa, Prognosis of medullary thyroid carcinoma: demographic, clinical, and pathologic predictors of survival in 1252 cases. Cancer 107(9), 2134–2142 (2006). doi:10.1002/cncr.22244

    Article  PubMed  Google Scholar 

  48. E. Kebebew, P.H. Ituarte, A.E. Siperstein, Q.Y. Duh, O.H. Clark, Medullary thyroid carcinoma: clinical characteristics, treatment, prognostic factors, and a comparison of staging systems. Cancer 88(5), 1139–1148 (2000)

    Article  CAS  PubMed  Google Scholar 

  49. A. Machens, H. Dralle, Biomarker-based risk stratification for previously untreated medullary thyroid cancer. J. Clin. Endocrinol. Metab. 95(6), 2655–2663 (2010). doi:10.1210/jc.2009-2368

    Article  CAS  PubMed  Google Scholar 

  50. Machens, A., Ukkat, J., Hauptmann, S., Dralle, H.: Abnormal carcinoembryonic antigen levels and medullary thyroid cancer progression: a multivariate analysis. Arch. Surg. 142(3), 289–293; discussion 294 (2007). doi:10.1001/archsurg.142.3.289

  51. S.I. Ismailov, N.R. Piulatova, Postoperative calcitonin study in medullary thyroid carcinoma. Endocr. Relat. Cancer 11(2), 357–363 (2004)

    Article  CAS  PubMed  Google Scholar 

  52. G. Pellegriti, S. Leboulleux, E. Baudin, N. Bellon, C. Scollo, J.P. Travagli, M. Schlumberger, Long-term outcome of medullary thyroid carcinoma in patients with normal postoperative medical imaging. Br. J. Cancer 88(10), 1537–1542 (2003). doi:10.1038/sj.bjc.6600930

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  53. A. Laure Giraudet, A. Al Ghulzan, A. Auperin, S. Leboulleux, A. Chehboun, F. Troalen, C. Dromain, J. Lumbroso, E. Baudin, M. Schlumberger, Progression of medullary thyroid carcinoma: assessment with calcitonin and carcinoembryonic antigen doubling times. Eur. J. Endocrinol. 158(2), 239–246 (2008). doi:10.1530/EJE-07-0667

    Article  PubMed  Google Scholar 

  54. J.A. Meijer, L.E. Bakker, G.D. Valk, W.W. de Herder, J.H. de Wilt, R.T. Netea-Maier, N. Schaper, E. Fliers, P. Lips, J.T. Plukker, T.P. Links, J.A. Smit, Radioactive iodine in the treatment of medullary thyroid carcinoma: a controlled multicenter study. Eur. J. Endocrinol. 168(5), 779–786 (2013). doi:10.1530/EJE-12-0943

    Article  CAS  PubMed  Google Scholar 

  55. D.L. Schwartz, V. Rana, S. Shaw, C. Yazbeck, K.K. Ang, W.H. Morrison, D.I. Rosenthal, A. Hoff, D.B. Evans, G.L. Clayman, A.S. Garden, S.I. Sherman, Postoperative radiotherapy for advanced medullary thyroid cancer–local disease control in the modern era. Head Neck 30(7), 883–888 (2008). doi:10.1002/hed.20791

    Article  PubMed  Google Scholar 

  56. T.P. Links, H.H. Verbeek, R.M. Hofstra, J.T. Plukker, Endocrine tumours: progressive metastatic medullary thyroid carcinoma: first- and second-line strategies. Eur. J. Endocrinol. 172(6), R241–R251 (2015). doi:10.1530/EJE-14-0726

    Article  CAS  PubMed  Google Scholar 

  57. M. Nocera, E. Baudin, G. Pellegriti, A.F. Cailleux, C. Mechelany-Corone, M. Schlumberger, Treatment of advanced medullary thyroid cancer with an alternating combination of doxorubicin-streptozocin and 5 FU-dacarbazine. Groupe d’Etude des Tumeurs a Calcitonine (GETC). Br. J. Cancer 83(6), 715–718 (2000). doi:10.1054/bjoc.2000.1314

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  58. Tuttle, R.M., Haddad, R.I., Ball, D.W., Byrd, D., Dickson, P., Duh, Q.Y., Ehya, H., Haymart, M., Hoh, C., Hunt, J.P., Iagaru, A., Kandeel, F., Kopp, P., Lamonica, D.M., Lydiatt, W.M., McCaffrey, J., Moley, J.F., Parks, L., Raeburn, C.D., Ridge, J.A., Ringel, M.D., Scheri, R.P., Shah, J.P., Sherman, S.I., Sturgeon, C., Waguespack, S.G., Wang, T.N., Wirth, L.J., Hoffmann, K.G., Hughes, M.: Thyroid carcinoma, version 2.2014. J. Natl. Compr. Canc. Netw. 12(12), 1671–1680; quiz 1680 (2014)

  59. S.A. Wells Jr, B.G. Robinson, R.F. Gagel, H. Dralle, J.A. Fagin, M. Santoro, E. Baudin, R. Elisei, B. Jarzab, J.R. Vasselli, J. Read, P. Langmuir, A.J. Ryan, M.J. Schlumberger, Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial. J. Clin. Oncol. 30(2), 134–141 (2012). doi:10.1200/JCO.2011.35.5040

    Article  CAS  PubMed  Google Scholar 

  60. R. Elisei, M.J. Schlumberger, S.P. Muller, P. Schoffski, M.S. Brose, M.H. Shah, L. Licitra, B. Jarzab, V. Medvedev, M.C. Kreissl, B. Niederle, E.E. Cohen, L.J. Wirth, H. Ali, C. Hessel, Y. Yaron, D. Ball, B. Nelkin, S.I. Sherman, Cabozantinib in progressive medullary thyroid cancer. J. Clin. Oncol. 31(29), 3639–3646 (2013). doi:10.1200/JCO.2012.48.4659

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  61. C. Durante, A. Paciaroni, K. Plasmati, F. Trulli, S. Filetti, Vandetanib: opening a new treatment practice in advanced medullary thyroid carcinoma. Endocrine 44(2), 334–342 (2013). doi:10.1007/s12020-013-9943-9

    Article  CAS  PubMed  Google Scholar 

  62. E. Fox, B.C. Widemann, M.K. Chuk, L. Marcus, A. Aikin, P.O. Whitcomb, M.J. Merino, M. Lodish, E. Dombi, S.M. Steinberg, S.A. Wells, F.M. Balis, Vandetanib in children and adolescents with multiple endocrine neoplasia type 2B associated medullary thyroid carcinoma. Clin. Cancer Res. 19(15), 4239–4248 (2013). doi:10.1158/1078-0432.CCR-13-0071

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  63. F. Carlomagno, T. Guida, S. Anaganti, G. Vecchio, A. Fusco, A.J. Ryan, M. Billaud, M. Santoro, Disease associated mutations at valine 804 in the RET receptor tyrosine kinase confer resistance to selective kinase inhibitors. Oncogene 23(36), 6056–6063 (2004). doi:10.1038/sj.onc.1207810

    Article  CAS  PubMed  Google Scholar 

  64. I. Martinez-Rodriguez, I. Banzo, J.M. Carril, Metabolic response demonstrated by 18F-FDG-PET/CT in metastatic medullary thyroid carcinoma under sorafenib therapy. Endocrine 44(1), 264–265 (2013). doi:10.1007/s12020-013-9946-6

    Article  CAS  PubMed  Google Scholar 

  65. E.T. Lam, M.D. Ringel, R.T. Kloos, T.W. Prior, M.V. Knopp, J. Liang, S. Sammet, N.C. Hall, P.E. Wakely Jr, V.V. Vasko, M. Saji, P.J. Snyder, L. Wei, D. Arbogast, M. Collamore, J.J. Wright, J.F. Moley, M.A. Villalona-Calero, M.H. Shah, Phase II clinical trial of sorafenib in metastatic medullary thyroid cancer. J. Clin. Oncol. 28(14), 2323–2330 (2010). doi:10.1200/JCO.2009.25.0068

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  66. F.C. Kelleher, R. McDermott, Response to sunitinib in medullary thyroid cancer. Ann. Intern. Med. 148(7), 567 (2008)

    Article  PubMed  Google Scholar 

  67. K.C. Bible, V.J. Suman, J.R. Molina, R.C. Smallridge, W.J. Maples, M.E. Menefee, J. Rubin, N. Karlin, K. Sideras, J.C. Morris 3rd, B. McIver, I. Hay, V. Fatourechi, J.K. Burton, K.P. Webster, C. Bieber, A.M. Traynor, P.J. Flynn, B. Cher Goh, C.R. Isham, P. Harris, C. Erlichman, M.C.C.C. Endocrine Malignancies Disease Oriented Group, C. the Mayo Phase, A multicenter phase 2 trial of pazopanib in metastatic and progressive medullary thyroid carcinoma: MC057H. J. Clin. Endocrinol. Metab. 99(5), 1687–1693 (2014). doi:10.1210/jc.2013-3713

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  68. L. Santarpia, G.A. Calin, L. Adam, L. Ye, A. Fusco, S. Giunti, C. Thaller, L. Paladini, X. Zhang, C. Jimenez, F. Trimarchi, A.K. El-Naggar, R.F. Gagel, A miRNA signature associated with human metastatic medullary thyroid carcinoma. Endocr. Relat. Cancer 20(6), 809–823 (2013). doi:10.1530/ERC-13-0357

    Article  CAS  PubMed  Google Scholar 

  69. C. Puppin, C. Durante, M. Sponziello, A. Verrienti, V. Pecce, E. Lavarone, F. Baldan, A.F. Campese, A. Boichard, L. Lacroix, D. Russo, S. Filetti, G. Damante, Overexpression of genes involved in miRNA biogenesis in medullary thyroid carcinomas with RET mutation. Endocrine 47(2), 528–536 (2014). doi:10.1007/s12020-014-0204-3

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Section of Endocrinology, Diabetes and Metabolism, Department of Medicine, The University of Chicago, Chicago, IL, USA

    Theodora Pappa

  2. Endocrine Unit, Department of Medical Therapeutics, Alexandra Hospital, Athens University School of Medicine, 80 Vassilissis Sofias Avenue, 11528, Athens, Greece

    Theodora Pappa & Maria Alevizaki

Authors
  1. Theodora Pappa
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Maria Alevizaki
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Maria Alevizaki.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Pappa, T., Alevizaki, M. Management of hereditary medullary thyroid carcinoma. Endocrine 53, 7–17 (2016). https://doi.org/10.1007/s12020-016-0873-1

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12020-016-0873-1

Keywords

Search

Navigation